共 100 条
[1]
Chi DS(2006)Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma Cancer 106 1933-1939
[2]
McCaughty K(2007)Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome Cancer 109 685-691
[3]
Diaz JP(2009)Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis Gynecol Oncol 112 265-274
[4]
Huh J(1991)Clinical relevance of the CA 125 assay in monitoring of ovarian cancer patients Am J Clin Oncol 14 111-114
[5]
Schwabenbauer S(1989)CA 125 reliability in predicting ovarian cancer recurrence Tumori 75 69-71
[6]
Hummer AJ(2010)Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial Lancet 376 1155-1163
[7]
Salani R(2010)Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias? Gynecol Oncol 117 336-340
[8]
Santillan A(1996)Defining progression of ovarian carcinoma during follow-up according to CA 125: a North Thames Ovary Group Study Ann Oncol 7 361-364
[9]
Zahurak ML(1998)Thin-section CT follow-up of metastatic ovarian carcinoma correlation with levels of CA-125 marker and clinical history Clin Imaging 22 364-370
[10]
Giuntoli RL(2007)Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma Eur J Nucl Med Mol Imaging 34 1396-1405